This grant from the DoD Neurofibromatosis Research Program (NFRP) is for supporting clinical trials aimed at decreasing Neurofibromatosis (NF) impact. The NFRP Clinical Trial Award funds studies evaluating new products, pharmacologic agents, devices, or emerging approaches to improve NF treatment and management. Projects can range from small proof-of-concept (Phase 0) to large-scale efficacy trials. Key areas of emphasis include cognitive/social dysfunction, drug discovery, tumor heterogeneity via genomics/epigenetics, post-adolescence manifestations, novel disease markers (imaging/proteomics), and pain. This award strictly supports clinical research, not preclinical studies, fostering direct translation to patient care.
Opportunity ID: 233116
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-NFRP-CTA |
| Funding Opportunity Title: | DoD Neurofibromatosis Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 03, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jul 11, 2013 |
| Current Closing Date for Applications: | Jul 11, 2013 |
| Archive Date: | Aug 10, 2013 |
| Estimated Total Program Funding: | $2,900,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The vision of the FY13 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; foster the next generation of NF investigators; promote translational and clinical studies to move promising ideas from bench to bedside; develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. Areas of Emphasis: The FY13 NFRP strongly encourages research applications that specifically address the critical needs of the NF community in one or more of the following Areas of Emphasis: Cognitive and social dysfunction in the setting of NF; Drug discovery for the treatment of NF; Heterogeneity of neurofibromas and other NF-related tumors using genomics, epigenetics, systems biology, or other similar approaches; Manifestations of NF post-adolescence; Novel disease markers such as imaging and proteomics of NF; Pain in the setting of NF. The NFRP Clinical Trial Award supports clinical trials with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising DoD FY13 NFRP Clinical Trial Award 4 new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept (i.e., pilot, first in human, or Phase 0) trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 233116 Full Announcement-1 -> nfrp_fy13 cta ind documentation form_gg.pdf
Folder 233116 Full Announcement-1 -> nfrp_fy13 cta pa_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00176394 | May 03, 2013 | Jul 11, 2013 | View |
Package 1
Mandatory forms
233116 RR_SF424_1_2-1.2.pdf
233116 PerformanceSite_1_4-1.4.pdf
233116 RR_Budget-1.1.pdf
233116 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
233116 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
